Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022 17:00 ET | Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 03, 2022 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Featured Image for www.gerdli.com
GerdLi: New Supplement for Heartburn Was Made by a Physician Who Sought Natural Heartburn Relief
November 01, 2022 09:00 ET | www.gerdli.com
SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Physician-engineered GerdLi is the natural answer for people who live with acid reflux and heartburn. It's a premium-formulated antacid that maintains gut...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
November 01, 2022 08:00 ET | Phathom Pharmaceuticals
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
October 24, 2022 08:00 ET | Phathom Pharmaceuticals
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S.Topline data for the primary endpoint is expected in Q1 2023 with full trial...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 23, 2022 12:01 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 18, 2022 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
GerdLi
GerdLi is Changing How People Manage Acid Reflux - Naturally
September 26, 2022 09:00 ET | GERDLI
SEATTLE, Sept. 26, 2022 (GLOBE NEWSWIRE) -- For millions of people, gastroesophageal reflux disease, or GERD, is a painful and uncomfortable condition that interrupts their life on a daily basis and...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
September 26, 2022 08:00 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 08:15 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...